# Pipeline Update: Anticipated Generic *Approvals/Launches/Patent 2015*

| Trade Name (generic name) Company(ies) | Therapeutic Use(s) | Estimated U.S. Sales† | Anticipated Generic Availability | Anticipated Generic Launch Type |
|---|---|---|---|---|
| Copaxone (glatiramer acetate) Teva | Relapsing-Remitting MS | $3.7 billion | June 2015 | Competitive |
| Namenda (memantine HCL) Allergan | Alzheimer's Disease | $1.8 billion | July 2015 | Competitive |
| TRAVATAN Z (travoprost) Alcon | Glaucoma; Ocular Hypertension | $485 million | H2 2015 | Exclusive |
| NASONEX (mometasone furoate) Schering/Merck | Seasonal & Perennial Allergic Rhinitis; Nasal Polyps | $1.2 billion | H2 2015 | Exclusive |
| WELCHOL (colesevelam hydrochloride) Daiichi Sankyo | Primary Hyperlipidemia; Type 2 Diabetes Mellitus | $574 million | H2 2015 | Exclusive |

†Financial data compiled from available annual and quarterly pharmaceutical company reports, IMS Health, BioMedTracker, Thomson Cortellis, analyst reports, and company press releases.

FDA approval; Exclusive = Denotes that one generic manufacturer will be eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval. Typically, the exclusive generic manufacturer will be eligible for a 180-day period of marketing exclusivity beginning either from the date it begins commercial marketing of the generic drug product, or from the date of a court decision finding the patent invalid, unenforceable or not infringed, whichever is first.



*© The Kroger Co. - Confidential*

# Pipeline Update: Anticipated Biosimilar *Approvals/Launches/Patent 2015*

| Trade Name (generic name) Company(ies) | Therapeutic Use(s) | Estimated U.S. Sales† | Anticipated Generic Availability | Anticipated Generic Launch Type |
|---|---|---|---|---|
| Neupogen (Filgrastim) Amgen | Neutropenia | $1 billion | July 2015 | Biosimilar |
| Rituxan (rituximab) Genentech | RA; CLL | $3.4 billion | September 2015 | Biosimilar |
| Neulasta (Pegfilgrastim) Amgen | Prophylaxis of Neutropenia | $3.7 billion | October 2015 | Biosimilar |
| Epogen (epoetin alfa) Amgen | Anemia ass. with Cancer, Kidney Disease & Zidovudine | $2.4 billion | H2 2015 | Biosimilar |
| Humira (adalimumab) Abbvie | RA; Crohn's Disease; UC; Plaque Psoriasis | $6.3 billion | December 2016 | Biosimilar |

†Financial data compiled from available annual and quarterly pharmaceutical company reports, IMS Health, BioMedTracker, Thomson Cortellis, analyst reports, and company press releases.

FDA approval; Exclusive = Denotes that one generic manufacturer will be eligible to launch a generic equivalent by the anticipated availability date assuming FDA approval. Typically, the exclusive generic manufacturer will be eligible for a 180-day period of marketing exclusivity beginning either from the date it begins commercial marketing of the generic drug product, or from the date of a court decision finding the patent invalid, unenforceable or not infringed, whichever is first.



*© The Kroger Co. - Confidential*